Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study
Latest Information Update: 29 Jun 2020
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms Direct III
- Sponsors Svelte Medical Systems
- 14 Feb 2019 Status changed from active, no longer recruiting to completed.
- 18 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 18 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.